摘要
目的观察奎硫平与氯氮平分别合并碳酸锂治疗躁狂症的临床疗效和不良反应。方法将符合CCMD-3中各型躁狂发作诊断标准的60例患者随机分成两组(每组30例),在使用碳酸锂的基础上分别联用奎硫平或氯氮平治疗6周。以Beck-Rafaelsen躁狂量表(BRMS)评定疗效,以不良反应量表(TESS)及相关辅助检查评价耐受性。结果治疗前后两组BRMS分值均有非常显著差异[治疗前奎硫平组BRMS总分为(28.8±8.7),6周后为(3.2±2.5),P<0.001;氯氮平组分别为(29.7±8.1),(3.1±2.6),P<0.001],两组治疗有效率相当;奎硫平组起效时间迟于氯氮平组,但不良反应较轻,治疗依从性好。结论奎硫平合并碳酸锂与氯氮平合并碳酸锂治疗躁狂症总体疗效相当,虽起效稍迟,但安全性高,治疗依从性好。
OBJECTIVE To compare the efficacy and side effects of quetiapine and clozapine both combined with lithium in patients with mania. METHODS Sixty patients meeting the criteria of CCMD-3 for maina were randomly divided into two groups（n = 30） ,which was assigned to receive quetiapine or clozapine both combined with lithium for 6 weeks. Clinical efficacy was evaluated with Bech-Rafaelsen mania rating scale（BRMS） and resistance was evaluated with treatment emergent symptom scale（TESS） and related examinations affiliated to the study, RESULTS The scores of BRMS of the two control groups showed quite significantly difference before and after treatment,while the rate of efficiency was comparative. The time of taking into effect in quetiapine group was later than that in clozapine group, but quetiapine showed slighter side effects and compliance was better compared with clozapine. CONCLUSION It is suggested that quetiapine combined with lithium is as effective as clozapine combined with lithium in patients with mania, and easily accepted by patients because of higher security and better compliance, though the time of taking into effect is later.
出处
《中国药学杂志》
CAS
CSCD
北大核心
2007年第11期877-878,共2页
Chinese Pharmaceutical Journal
